Cell Viability Assays Market Size & Share, by Product (Consumables, Instrument); Application (Drug Discovery & Development, Stem Cell Research) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2025-2037

  • Report ID: 4785
  • Published Date: Nov 08, 2024
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2025-2037

Cell Viability Assays Market size was over USD 1.87 billion in 2024 and is projected to reach USD 5.6 billion by 2037, witnessing around 8.8% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of cell viability assays is assessed at USD 2 billion. The market growth is due to growing interest in developing cell therapy technologies for the treatment of COVID-19 and its increasing acceptance. For example, in 2020, Calidi Biotherapeutics Inc. announced that the Food and Drug Administration had granted provisional marketing authorization for its partner Personalized Stem Cells Inc.'s Investigational New Product Application to be used with stem cell therapy on COVID-19 and pneumonia patients. COVID-19 was reported to WHO by 761,769,759 confirmed cases including 6,784,181 deaths across the globe.

In addition, investment in the area of cell-based research and funding has increased. For example, the California Center for Regenerative Medicine said in February 2022 that it would invest around USD 10 million on a cell therapy study to help patients who have throat cancer recover from terrible radiation side effects.


Cell Viability Assays Market
Get more information on this report: Request Free Sample PDF

Cell Viability Assays Sector: Growth Drivers and Challenges

Growth Drivers

  • Growing Geriatric Population- By 2030, one in six people on the earth would be 60 years of age or older, according to the World Health Organisation. There will likely be 1.4 billion persons who are 60 years of age or older by 2022, up from 1 billion in 2020. Cells make up the majority of tissues. All cells alter as they become older. They are growing larger while losing the ability to divide and multiply. Inside the cells, there are a number of pigments and fatty substances as well as other modifications. With increasing age, many of the cells stop functioning properly or start working in an unnatural way.
  • Rise in Prevalence of Cancer- During the forecast period, an increase in cancer patients is anticipated. According to the World Health Organization, almost 10 million deaths, or roughly one in six deaths, would be caused by cancer in 2020, making it the top cause of death globally.
  • Surge in Need for Stem Cell Transplant- A total of 12,000 stem cell transplants have taken place around the world in the last 50 years. Around 49,000 transplants have already been performed each year, and the number is growing.

Challenges

  • Shortage of Technical Specialists and Professionals to Run Instruments- The global shortage of healthcare professionals can be attributed to the fact that many countries do not invest in health worker education and training. The lack of alignment between employment and education policies in view of the needs of workers and healthcare systems is also a major issue. The situation has deteriorated further since healthcare personnel is difficult to bring into remote, underutilised areas and in the countryside. In addition, there has been an increase of health workers' migration that could lead to a shortage in particular for poor and less well-developed countries.
  • Assays for the Viability of Cells are very Expensive which may Hinder the Growth of the Market
  • Misunderstanding of People's Awareness is One of the Retraining Factor

Cell Viability Assays Market: Key Insights

Base Year

2024

Forecast Year

2025-2037

CAGR

8.8%

Base Year Market Size (2024)

USD 1.87 billion

Forecast Year Market Size (2037)

USD 5.6 billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Cell Viability Assays Segmentation

Application (Drug Discovery & Development, Stem Cell Research)

The stem cell research is anticipated to account for 52% share of the global cell viability assays market during the forecast period. The growth of this category can be attributed to increasing investments in stem cell research, and the Novo Nordisk Foundation's investment is expected to reach as high as USD 340 million over 10 years for the construction of a global Stem Cell Research Facility by 2022. The growth segment is also projected to benefit from an increase in the incidence of cardiovascular disease. The problems with the blood vessels cause cardiac disease most of the time. Stem cells that appear and function as normal blood vessels are used for the production of new blood vessels. In view of their ability to repair or regenerate various human tissues, stem cells from the bank can be used as a tool for people who are affected by conditions like vascular and cardiac disease.

Product (Consumables, Instrument)

Cell viability assays market from the consumables segment is expected to hold the largest share by the end of 2037. In view of the application of consumables for diagnostics, stem cell research, and pharmaceutical and biopharmaceutical research in particular, this segment is expected to experience significant growth with approximately 55 % market share over the forecast period. A large selection of nontoxic, ready-to-use, and highly immediate results reagents for cell viability assays is also available from a number of market participants.

Our in-depth analysis of the global market includes the following segments:

          Product

  • Consumables
  • Instrument  

          Application

  • Drug Discovery & Development
  • Stem Cell Research

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Cell Viability Assays Industry - Regional Synopsis

North American Market Forecast

North America region is projected to account for 38% share of the cell viability assays market, supported by an increase in cancer cases and infrastructure for clinical and laboratory research with a quality that has not yet been achieved in North America. a projected 1,806,590 new instances of cancer were identified in the US in 2020, while 606,520 people passed away from the illness. Consequently, it is expected that growth in the product market will be driven by demand for cell-based therapies. The expansion of the research and development capability, coupled with increasing expenditure on developing healthcare infrastructure, has led to a growing need for cell viability assays.

APAC Market Statistics

The cell viability assays market in Asia Pacific is attributed to have about 28% share during the forecast period. The growth of the market may be due to a growing government initiative, which seeks to inform people about an increasing incidence of cancer and different types of cell therapy available. In addition, the government in these areas makes a great deal of investment in research and development. However, cell therapies such as stem cell therapy are also being funded by a variety of private sectors. Consequently, the growth of the market in this region is estimated to be stimulated by these factors. In addition, the growth of this industry is projected to be driven by an increase in demand for biopharmaceutical products as well as a presence of cutting-edge research and healthcare infrastructure throughout the region.

Research Nester
Cell Viability Assays Market  Size
Get more information on this report: Request Free Sample PDF

Companies Dominating the Cell Viability Assays Landscape

    • Thermo Fisher Scientific Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Agilent Technologies, Inc.
    • Bio-Rad Laboratories Inc.
    • Merck KGaA
    • Becton, Dickinson and Company (BD)
    • PerkinElmer Inc.
    • Promega Corporation
    • Biotium, Inc.
    • Creative Bioarray
    • Abcam Plc.

In the News

  • The improved applied Biosystems HIV-1 Genotyping Kit was released by Thermo Fisher Scientific, Inc. The new kit complements the previously released Applied Biosystems MagMax Viral/Pathogen Nucleic Acid Isolation Kit for HIV-1 Blood Sports. With the aid of this device, labs may monitor HIV mutations to antiretroviral treatment inhibitors using a cutting-edge method for drug resistance surveillance. 
  • The BD Rhapsody TCR/BCR Multiomic Assay, a cutting-edge set of reagents that enables researchers to more easily and thoroughly analyze crucial immune system cells, was released by BD (Becton, Dickinson, and Company), a leading global medical technology company. This assay would then be used to advance research on autoimmune disorders, immune oncology, and infectious diseases.

Author Credits:  Radhika Pawar


  • Report ID: 4785
  • Published Date: Nov 08, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of cell viability assays is assessed at USD 2 billion.

The cell viability assays market size was over USD 1.87 billion in 2024 and is projected to reach USD 5.6 billion by 2037, witnessing around 8.8% CAGR during the forecast period i.e., between 2025-2037. The market growth can be attributed to growing geriatric population, rise in prevalence of cancer, surge in need for stem cell transplant, and others.

North America industry is set to dominate majority revenue share of 38% by 2037, due to a demand for cell-based therapies in the region.

The major players in the market include Thermo Fisher Scientific Inc., Agilent Technologies, Inc., Bio-Rad Laboratories Inc., Merck KGaA, Becton, Dickinson and Company (BD), PerkinElmer Inc., Promega Corporation, Biotium, Inc., Creative Bioarray, Abcam Plc.
Cell Viability Assays Market Report Scope
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample